The latest data point for NVO's PEG Ratio in Q4'25 stands at 0.39, reflecting a moderate positive valuation signal compared to the prior quarter's negative reading of -0.80 in Q3'25. This uptick suggests improving growth expectations relative to earnings multiples at the end of the fiscal year. Over the period from Q1'23 to Q4'25, the PEG Ratio has exhibited high volatility, oscillating between deep negative values (as low as -17.82 in Q4'23) and positive peaks (reaching 7.13 in Q4'24), indicative of fluctuating market perceptions of NVO's growth prospects. Notable patterns include recurring swings from negative to positive territory, with an overall lack of sustained trend—early quarters showed extreme negativity possibly tied to earnings surprises, while recent data stabilizes around neutral levels, highlighting the metric's sensitivity to forward-looking adjustments in the pharmaceutical sector.